logo

Has Pfizer played a key role in the evolution of global pharmaceutical patent rules?

Sunday, March 21, 2021
By Gus Fisher
YES

Global rules governing intellectual property laws for vaccines and pharmaceuticals resulted from years of trade negotiations leading to what’s known as the TRIPS Agreement in 1994. A key figure then backing the agreement was the chairman of Pfizer, Edmund Pratt, who wanted intellectual property protections against generic-drug manufacturers in emerging markets.

Pratt was named to a U.S. presidential advisory committee on trade in 1979. In 1986, he co-founded the Intellectual Property Committee, a group of 13 large corporations advocating intellectual property laws in the General Agreement on Tariffs and Trade, which was succeeded by the World Trade Organization in 1995.

Other Pfizer executives pushed for strong patent laws in influential groups within both the U.S. government and intergovernmental bodies such as the Organization for Economic Cooperation and Development.

This fact brief is responsive to conversations such as this one.
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
FACT BRIEF BY
facebook
twitter
email
email